LNAI

Business Context and Reporting Period

Lunai Bioworks Inc. (LNAI) filed a Form 8-K on May 8, 2026, reporting the results of a special meeting of stockholders held on the same date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes and Voting Results

Stockholders voted on two proposals to address potential listing compliance issues:

• Proposal 1: Approval of an amendment to the Certificate of Incorporation to effect a reverse stock split. The ratio is set between 1-for-3 and 1-for-30, with the Board of Directors retaining sole discretion to determine the exact ratio.
• Proposal 2: Approval to adjourn the special meeting if necessary to solicit additional proxies.

Voting Results:

Outlook, Risks, and Management Commentary

Management indicated that the reverse stock split is intended to help the company regain or maintain compliance with Nasdaq continued listing requirements, specifically the Bid Price Rule. The filing includes forward-looking statements subject to risks and uncertainties, including:

• The possibility that the reverse stock split may not result in compliance with the Bid Price Rule.
• Consequences related to a Mandatory Panel Monitor.
• General risks associated with the continued listing of the company's common stock on The Nasdaq Capital Market.

Investor Verification Checklist

• Verify the exact reverse stock split ratio once determined by the Board of Directors.
• Confirm the company's current bid price and whether the split achieves Nasdaq compliance.
• Review the status of the Mandatory Panel Monitor mentioned in the risk factors.
• Check subsequent filings for the effective date of the reverse stock split and any changes to the number of outstanding shares.